DIA-ChIP seeks to develop state-of-the-art molecular techniques for the routine high-throughput analysis of clinical samples for advanced molecular diagnosis and biomedical research. This will be achieved through a collaborative p...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CANCER-ID
Cancer treatment and monitoring through identification of ci...
21M€
Cerrado
CANCER-ID
Cancer treatment and monitoring through identification of ci...
21M€
Cerrado
FG_WIT
AUTOMATED PROTOTYPE OF CANCER DETECTION FROM CTDNA
75K€
Cerrado
RTI2018-094533-A-I00
DESARROLLO DE UN ENSAYO MICROFLUIDICO FUNCIONAL EN CELULAS P...
169K€
Cerrado
CPP2021-009037
DESARROLLO DE TEST DIAGNÓSTICOS BASADOS EN DNA PARA PERSONAL...
474K€
Cerrado
PDC2021-121424-I00
BIOPSIA Y TEJIDO EN UN CHIP MAS BIOSENSORES MULTIPLEXADOS IN...
138K€
Cerrado
Información proyecto DIA-CHIP
Líder del proyecto
SWANSEA UNIVERSITY
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
731K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
DIA-ChIP seeks to develop state-of-the-art molecular techniques for the routine high-throughput analysis of clinical samples for advanced molecular diagnosis and biomedical research. This will be achieved through a collaborative partnership between academic, SME and public health partners interacting through the IAPP, and the secondments and recruitments it supports. New molecular diagnostics in clinical pathology need to be robust, cost effective and offer significant advantages over existing techniques. With the move towards personalised medicine the specificity of diagnosis will need to be enhanced significantly, yet in the short to medium term will need to be compatible with current gold standards of analysis. In this project the focus will be on the most important cancer affecting the female European population – Breast Cancer. The ability to analyse archived clinical material is currently limited to immuno-histochemistry and quantification the native biomolecules (DNA, RNA, protein). The advent of functional characterisation of these molecules i.e. DNA-protein interactions and DNA status will provide information to enhance diagnostic histopathology. Application to archival material will provide access to a hugely valuable resource and will contribute significantly to scientific understanding of disease processes by allowing the examination of large patient cohorts, and by facilitating direct comparison to model systems. Also by examining patient samples in concert with model human cell culture systems, alternatives to animal model systems will be developed. DIA-ChIP features the creation of a strategic partnership between 4 groups that is critical in realising the project. The partners will develop strong long-term collaborative links for future research projects and intellectual exchange that will serve to strengthen each of the partners positions. The ultimate aim is to ensure long-term co-operation between all sectors -Business, Academic, Public Health